This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Learn about ONCOTICE® (2-8 x 108 CFU Tice BCG)

Updated on 08/02/2019

ONCOLOGY
Oncotice Banner

Indication

  • ONCOTICE is indicated for treatment of primary or concurrent carcinoma-in-situ of the urinary bladder and for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (Stage Ta (grade 2 or 3) or T1 (grade 1, 2 or 3)) after
    transurethral resection
  • ONCOTICE is only recommended for stage Ta grade 1 papillary tumours, when there is judged to be a high risk of tumour recurrence

Reconstitution and instillation of ONCOTICE

The animated video is intended to give guidance on the reconstitution and instillation of ONCOTICE into
the bladder.

Prescribing Information

Please see the full product Summary of Product Characteristics for further information on the use and administration of ONCOTICE.

Related content

 

Supporting documentation

Prescribing Information | Summary of Product Characteristics

GB-XTB-00001 | Date of Preparation: February 2019